menu
    • menu
    [{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Janssen Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP-1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Janssen Biotech"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ EMD Serono","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ EMD Serono"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Pierre Fabre"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Brigimadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foundation Medicine \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Foundation Medicine \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MET receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Repare Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Foundation Medicine \/ Repare Therapeutics"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Enzomenib","moa":"MLL-Menin interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foundation Medicine \/ Sumitomo Pharma America","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Sumitomo Pharma America"}]

    Find Clinical Drug Pipeline Developments & Deals by Foundation Medicine

    Menu

    Foundation Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzomenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sumitomo Pharma America

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine, Sumitomo Collaborate on Acute Leukemia Treatment

                            Details : The collaboration aims to develop the FoundationOne Heme platform as a companion diagnostic to identify patients with AML with a NPM1 mutations for potential treatment with DSP-5336 (enzomenib).

                            Product Name : DSP-5336

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 18, 2025

                            Lead Product(s) : Enzomenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sumitomo Pharma America

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lunresertib,Camonsertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Repare Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine Partners with Repare for Genomic Profiling and Companion Diagnostic

                            Details : The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.

                            Product Name : RP-6306

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 06, 2024

                            Lead Product(s) : Lunresertib,Camonsertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Repare Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tepotinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : EMD Serono

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves FoundationOne®Liquid CDx for TEPMETKO® in MET Exon 14 NSCLC

                            Details : Tepmetko (tepotinib) is a kinase inhibitor indicated for the treatment of adult patients with NSCLC harboring mesenchymalepithelial transition (MET) exon 14 skipping alterations.

                            Product Name : Tepmetko

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 18, 2024

                            Lead Product(s) : Tepotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : EMD Serono

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inavolisib,Fulvestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves FoundationOne®Liquid CDx As Diagnostic For Itovebi™ in Breast Cancer

                            Details : FoundationOne®Liquid CDx to be used as a companion diagnostic for Itovebi (inavolisib) for adults with endocrine-resistant, PIK3CA-mutated HR+/HER2-breast Cancer.

                            Product Name : Itovebi

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 10, 2024

                            Lead Product(s) : Inavolisib,Fulvestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Janssen Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves FoundationOne®Liquid CDx as Companion Diagnostic for AKEEGA®

                            Details : Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.

                            Product Name : Akeega

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 07, 2024

                            Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Janssen Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capivasertib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca’s Truqap™ (capivasertib) in...

                            Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.

                            Product Name : Truqap

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 20, 2023

                            Lead Product(s) : Capivasertib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in...

                            Details : The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimet...

                            Product Name : Braftovi

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 15, 2023

                            Lead Product(s) : Encorafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selinexor

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Karyopharm Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne®CDx as a Co...

                            Details : Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.

                            Product Name : Xpovio

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            October 01, 2023

                            Lead Product(s) : Selinexor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Karyopharm Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Cetuximab,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. Food and Drug Administration (FDA) Approves FoundationOneLiquid CDx as a Companion Diagnostic for Pfizerâ...

                            Details : Braftovi (Encorafenib) Is An Oral Small Molecule Braf Kinase Inhibitor And Combination With Cetuximab Used for Patients With Patients With Braf V600E Alterations In Metastatic Colorectal Cancer.

                            Product Name : Braftovi

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 06, 2023

                            Lead Product(s) : Encorafenib,Cetuximab,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Foundation Medicine

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brigimadlin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer C...

                            Details : The Partnership will focus on developing FoundationOne®CDx as a companion diagnostic for Boehringer Ingelheim’s investigational MDM2-p53 antagonist, BI 907828, an investigational, oral, small molecule MDM2-p53 antagonist.

                            Product Name : BI 907828

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 19, 2023

                            Lead Product(s) : Brigimadlin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth